biotech / news / / The Manila Times
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children.
The FDA expanded Tzield's approval to children as young as one year with stage 2 T1D.
KEY POINTS
- Tzield is now the first disease-modifying therapy for stage 2 T1D in children aged one and above.
- Approval was based on one-year data from the PETITE-T1D phase 4 study in young children.
- Previously, Tzield was only approved for patients eight years and older with stage 2 T1D.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →